X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs J.B.CHEMICALS - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER J.B.CHEMICALS PFIZER/
J.B.CHEMICALS
 
P/E (TTM) x 34.2 17.3 198.1% View Chart
P/BV x 4.8 2.3 206.8% View Chart
Dividend Yield % 0.7 0.2 425.3%  

Financials

 PFIZER   J.B.CHEMICALS
EQUITY SHARE DATA
    PFIZER
Mar-18
J.B.CHEMICALS
Mar-16
PFIZER/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs2,365318 743.5%   
Low Rs1,625200 814.5%   
Sales per share (Unadj.) Rs430.3148.0 290.8%  
Earnings per share (Unadj.) Rs78.719.1 412.4%  
Cash flow per share (Unadj.) Rs93.223.9 389.1%  
Dividends per share (Unadj.) Rs20.000.50 4,000.0%  
Dividend yield (eoy) %1.00.2 518.9%  
Book value per share (Unadj.) Rs586.5128.9 454.8%  
Shares outstanding (eoy) m45.7584.82 53.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.61.7 265.1%   
Avg P/E ratio x25.313.6 186.9%  
P/CF ratio (eoy) x21.410.8 198.1%  
Price / Book Value ratio x3.42.0 169.5%  
Dividend payout %25.42.6 969.9%   
Avg Mkt Cap Rs m91,27121,951 415.8%   
No. of employees `0002.62.7 96.2%   
Total wages/salary Rs m3,1431,841 170.7%   
Avg. sales/employee Rs Th7,484.84,590.9 163.0%   
Avg. wages/employee Rs Th1,195.0673.4 177.4%   
Avg. net profit/employee Rs Th1,369.1592.1 231.2%   
INCOME DATA
Net Sales Rs m19,68512,551 156.8%  
Other income Rs m1,143542 211.0%   
Total revenues Rs m20,82813,093 159.1%   
Gross profit Rs m5,0032,055 243.5%  
Depreciation Rs m663412 160.6%   
Interest Rs m496 4.4%   
Profit before tax Rs m5,4792,088 262.4%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878469 400.4%   
Profit after tax Rs m3,6011,619 222.4%  
Gross profit margin %25.416.4 155.2%  
Effective tax rate %34.322.5 152.6%   
Net profit margin %18.312.9 141.8%  
BALANCE SHEET DATA
Current assets Rs m24,1677,778 310.7%   
Current liabilities Rs m9,5444,358 219.0%   
Net working cap to sales %74.327.2 272.7%  
Current ratio x2.51.8 141.9%  
Inventory Days Days5555 100.8%  
Debtors Days Days2980 35.9%  
Net fixed assets Rs m9,5145,713 166.5%   
Share capital Rs m458170 269.8%   
"Free" reserves Rs m26,37510,547 250.1%   
Net worth Rs m26,83210,937 245.3%   
Long term debt Rs m250-   
Total assets Rs m36,90015,574 236.9%  
Interest coverage x1,305.522.8 5,721.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.8 66.2%   
Return on assets %9.811.0 88.7%  
Return on equity %13.414.8 90.7%  
Return on capital %20.420.0 102.3%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m226,169 0.4%   
Fx outflow Rs m1,4891,285 115.8%   
Net fx Rs m-1,4664,884 -30.0%   
CASH FLOW
From Operations Rs m3,3181,397 237.6%  
From Investments Rs m-2,383-320 744.0%  
From Financial Activity Rs m-1,104-1,196 92.3%  
Net Cashflow Rs m-169-102 164.7%  

Share Holding

Indian Promoters % 0.0 55.4 -  
Foreign collaborators % 63.9 0.3 21,300.0%  
Indian inst/Mut Fund % 7.5 3.4 221.2%  
FIIs % 4.9 3.9 125.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 37.0 64.1%  
Shareholders   85,207 30,437 279.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 21, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS